The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

CDDF Multi-Stakeholder Workshop

Histology-independent Drug Development – Is this the future for cancer drugs?

14 – 15 November 2022, Hybrid Workshop

 

Recordings

 

SESSION 1: LESSONS LEARNED FROM PREVIOUS TRIALS - SUCCESSES AND FAILURES

Introduction / overview of successes: Alastair Greystoke (Newcaslte University, UK)

Regulatory perspective: Elias Pean (EMA, NL)

Moving from experimental phase to evidence-based practice, a payer’s perspective: Sahar Barjesteh van Waalwijk van Doorn-Khosrovani (CZ, NL) – the speaker didn’t give consent to share the presentation

Session1: Panel discussion

 

SESSION 2: BIOMARKER DEVELOPMENT AND OPTIMISATION

SESSION 3: TRIALS DESIGN - BASKET OR UMBRELLA FOR OPTIMAL PROGRESS

Regulatory perspective: Dr Theodor Framke (EMA, NL) – the speaker didn’t give his consent to share the presentation

Academic perspective: Prof Lucinda Billingham (University of Birmingham, UK)

Early phase side of drug development – Industry perspective: Richardus Vonk (Bayer, DE)

Session 3: Panel discussion

SESSION 4: LEVERAGING THE POTENTIAL OF PRECISION MEDICINE: ENSURING EQUIT Y OF ACCESS TO PRECISION DIAGNOSTICS AND TREATMENTS FOR PATIENTS

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

info@cddf.org
Tel: +32 2 880 62 70